Considerations in Technology Transfer Concerning Biopharmaceuticals: The University Perspective
Panel
Panel 7: Technology Transfer and the Role of Universities
Moderator
Ruth Okediji, Jeremiah Smith Jr. Professor of Law and Co-Director of the Berkman Klein Center, Harvard Law
Description
The US pharmaceutical industry continues to face a number of challenges which include decreasing returns, declining sales, increasing development costs, the threat of price controls, an increasingly risk averse FDA, lack of internal pipeline diversity, patent expirations, and industry consolidation. With fewer truly innovative drug discovery programs being initiated internally, big pharma is more and more reliant on small, development stage biotech companies for their future product pipelines. Biotech companies however are facing challenges themselves, not the least of which is the paucity of true early-stage capital to fund technology development, pre-clinical drug discovery and product platform innovation. As a result, top tier research universities have had to step up to address the challenge of supporting the translational research needed to fill the growing gap between fundamental research undertaken within the academy and the innovation that fuels early stage companies and the future of therapeutics, diagnostics and medical device discovery and development. At UC Davis, we see an important element of our public mission being to transform cutting edge biological research into products or services that can positively change the lives of those in our community and create economic impact in California and beyond. Effective and efficient technology commercialization processes lie at the heart of how we are working to transform innovation into impact.
Location
Pacific McGeorge School of Law, Lecture Hall, 3200 Fifth Ave., Sacramento, CA
Considerations in Technology Transfer Concerning Biopharmaceuticals: The University Perspective
Pacific McGeorge School of Law, Lecture Hall, 3200 Fifth Ave., Sacramento, CA
The US pharmaceutical industry continues to face a number of challenges which include decreasing returns, declining sales, increasing development costs, the threat of price controls, an increasingly risk averse FDA, lack of internal pipeline diversity, patent expirations, and industry consolidation. With fewer truly innovative drug discovery programs being initiated internally, big pharma is more and more reliant on small, development stage biotech companies for their future product pipelines. Biotech companies however are facing challenges themselves, not the least of which is the paucity of true early-stage capital to fund technology development, pre-clinical drug discovery and product platform innovation. As a result, top tier research universities have had to step up to address the challenge of supporting the translational research needed to fill the growing gap between fundamental research undertaken within the academy and the innovation that fuels early stage companies and the future of therapeutics, diagnostics and medical device discovery and development. At UC Davis, we see an important element of our public mission being to transform cutting edge biological research into products or services that can positively change the lives of those in our community and create economic impact in California and beyond. Effective and efficient technology commercialization processes lie at the heart of how we are working to transform innovation into impact.
Speaker Bio
Dr. Dushyant Pathak is Associate Vice Chancellor of Research and Executive Director of Venture Catalyst, at UC Davis, with responsibility for comprehensive campus-wide technology commercialization and economic impact activities. Dushyant has over 15 years of business experience including with Fortune-500, early-stage and start-up companies, in roles as CEO, leading business development, and directing clinical project operations and product development. He has been on leadership teams responsible for successful M&A and a NASDAQ IPO. He has actively participated in raising over $100 million in investment capital and worked in venture capital with Connecticut Innovations and as the first Entrepreneur-in-Residence at Mission Bay Capital. He was a member of the research faculty at Yale University, adjunct professor at the University of San Francisco’s School of Management and visiting professor at Berkeley Haas School of Business. He received an MBA from Haas, a Ph.D. from Northwestern University and a B.A. from Bennington College.